# US 2003/0211457 A1 · Methods and kits for testing mutagenicity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211457 A1
- Document ID: US20030211457A1
- Status: Published application
- Kind: A1
- Application number: 10/273,601
- Filed: 2002-10-17
- Published: 2003-11-13
- Earliest claimed: 2002-04-08
- Assignees: Transgenomic, Inc.
- Inventors: Luman Wing; Michael Saghbini
- Web page: https://patentgrep.com/patent/US20030211457A1

## CPC

- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

In one aspect, methods and kits for determining the mutagenic potential of a test substance. The method includes exposing a tester strain (such as Salmonella typhimurium) to the substance, wherein the tester strain includes a gene (such as the histidine gene) having a preexisting mutation conferring auxotrophy, and the mutation is located at a pre-determined position in the gene, growing the tester strain in growth media lacking histidine, and detecting the presence of a back-mutation at the position by analysis of the nucleic acid. The tester strain can be selected from TA98, TA100, TA102 TA1535, TA1537, TA1538, and TA97. The test substance can be any of a wide variety of compounds such as petroleum extracts, pesticides, cosmetics, adhesives, herbicides, hair dyes, and pharmaceuticals. The detecting step can include one or more conventional mutation detection methods. Also provided are kits for conducting the method. The kits can include one or more tester strains, PCR primers, positive control compounds, and DNA polymerase.

## Claims

### Claim 1

A method for screening a test substance suspected of being a mutagen, the method comprising:
a) providing a tester strain of Salmonella typhimurium,
wherein said tester strain comprises a histidine gene having a preexisting mutation conferring auxotrophy, said mutation located at a pre-determined position in said gene,
b) determining a first level of back-mutation in the nucleic acid sequence of said gene in tester strain which have not been exposed to said substance,
c) exposing tester strain to said substance and determining a second level of back-mutation in the nucleic acid sequence of said gene,
d) comparing said first level with said second level.

### Claim 2 (depends on 1)

The method of claim 1 wherein said preexisting mutation is a base substitution or a frame shift mutation.

### Claim 3 (depends on 1)

The method of claim 1 including amplifying a pre-selected region of said histidine gene, wherein said position is within said region.

### Claim 4 (depends on 3)

The method of claim 3 wherein said amplifying is by the polymerase chain reaction.

### Claim 5 (depends on 1)

The method of claim 1 wherein determining in step (b) and step (c) includes a method selected from the group consisting of direct sequencing, minisequencing, pyrosequencing, single-stranded conformation polymorphism, denaturing gradient gel electrophoresis, chemical cleavage, cleavage by mismatch endonuclease, allele specific oligonucleotides, ligase mediated detection of mutations, invader assay, and denaturing high performance liquid chromatography.

### Claim 6 (depends on 1)

The method of claim 1 wherein determining in step (b) and step (c) includes performing denaturing high performance liquid chromatography.

### Claim 7 (depends on 1)

The method of claim 1 wherein said test substance is selected from the group consisting of petroleum extract, pesticides, cosmetics, adhesives, food coloring, herbicides, hair dyes, and pharmaceuticals.

### Claim 8 (depends on 1)

The method of claim 1 wherein said test substance comprises petroleum extract.

### Claim 9 (depends on 1)

The method of claim 1 wherein said tester strain is selected from the group consisting of TA98, TA100, TA102, TA104, TA1535, TA1537, TA1538, and TA97.

### Claim 10 (depends on 1)

The method of claim 1 wherein determining in step (b) and step (c) includes S9 homogenate.

### Claim 11 (depends on 1)

The method of claim 1 further including correlating the level of DNA having said back-mutation with the concentration of said substance in said media.

### Claim 12 (depends on 1)

The method of claim 1 wherein step (d) further includes determining whether said test substance is a mutagen.

### Claim 13 (depends on 1)

The method of claim 1 wherein said test compound comprises a hydrocarbon mixture, and wherein said method includes extracting the hydrocarbon mixture with a solvent effective for removing mutagenic compounds from said mixture.

### Claim 14 (depends on 13)

The method of claim 13 wherein an optimal amount of induced liver homogenate is included as a metabolic activator in said incubation.

### Claim 15 (depends on 13)

The method described in claim 13 wherein said solvent is DMSO, said mutant strain is Salmonella typhimurium TA98, and said liver homogenate is Aroclor 1254-induced rat S9.

### Claim 16 (depends on 13)

The method described in claim 13 wherein said solvent is DMSO, said mutant strain is Salmonella typhimurium TA98, and said liver homogenate is Aroclor 1254-induced hamster S9.

### Claim 17 (depends on 13)

The method described in claim 13 wherein said solvent is DMSO, said mutant strain is Salmonella typhimurium TA102, and said liver homogenate is Aroclor 1254-induced rat S9.

### Claim 18 (depends on 13)

The method described in claim 13 wherein said solvent is DMSO, said mutant strain is Salmonella typhimurium TA102, and said liver homogenate is Aroclor 1254-induced hamster S9.

### Claim 19 (depends on 13)

The method described in claim 13 wherein said hydrocarbon mixture is of petroleum origin.

### Claim 20 (depends on 13)

The method described in claim 13 wherein said solvent is selected from the group consisting of DMSO, 1-methyl-2-pyrrolidinone and N,N-dimethylformamide, said mutant strain is selected from the group consisting of Salmonella typhimurium TA98 and TA102, and said induced liver homogenate is selected from the group consisting of Aroclor 1254-induced rat liver S9 and Aroclor 1254-induced hamster liver S9.

### Claim 21

A method for determining the mutagenic potential of a putative mutagen, the method comprising:
a) exposing a tester strain of Salmonella typhimurium to said mutagen,
wherein said tester strain comprises a histidine gene having a preexisting mutation conferring auxotrophy, said mutation located at a predetermined position in said gene,
b) growing said tester strain in growth media lacking histidine,
c) detecting the presence of a back-mutation at said position, wherein the presence of said back-mutation is correlated with the mutagenic potential of said mutagen.

### Claim 22 (depends on 21)

The method of claim 21 wherein said putative mutagen comprises ultraviolet light.

### Claim 23

A method for evaluating the potential mutagenicity of a test compound, which method comprises:
a) subjecting an inoculum of a histidine deficient mutant strain of Salmonella typhimurium to incubation in the presence of said compound wherein said strain comprises DNA possessing a preexisting mutation at a pre-determined position in the histidine biosynthetic operon,
b) determining the presence in said incubation of DNA having a back-mutation at said position, wherein said DNA having a back-mutation is indicative of the mutagenicity of said compound.

### Claim 24 (depends on 23)

The method of claim 23 wherein said test compound comprises a hydrocarbon mixture, and wherein said method includes extracting the hydrocarbon mixture with a solvent effective for removing mutagenic compounds from said mixture.

### Claim 25 (depends on 23)

The method of claim 23 wherein an optimal amount of induced liver homogenate is included as a metabolic activator in said incubation.

### Claim 26 (depends on 24)

The method described in claim 24 wherein said hydrocarbon mixture is of petroleum origin.

### Claim 27

A method for evaluating the potential mutagenicity of a hydrocarbon mixture, which method comprises:
extracting the hydrocarbon mixture with a solvent effective for removing mutagenic compounds from said mixture, wherein an extract is obtained;
subjecting an inoculum of a histidine deficient mutant strain of Salmonella typhimurium to incubation in the presence of a sample of said extract and, as metabolic activator, an optimal amount of induced liver homogenate, wherein said strain comprises DNA possessing a preexisting mutation at a pre-determined position in the histidine biosynthetic operon;
determining the presence in said incubation of DNA having a back-mutation at said position, wherein said DNA having a back-mutation is indicative of the mutagenicity of said mixture.

### Claim 28

A method for screening a hydrocarbon mixture suspected of being a mutagen, the method comprising:
a) extracting the hydrocarbon mixture with a solvent effective for removing mutagenic compounds from said mixture, wherein an extract is obtained;
b) providing a tester strain of Salmonella typhimurium,
wherein said tester strain comprises a histidine gene having a preexisting mutation conferring auxotrophy, said mutation located at a pre-determined position in said gene,
c) determining a first level of back-mutation in the nucleic acid sequence of said gene in tester strain which have not been exposed to said extract,
d) exposing tester strain to said extract and determining a second level of back-mutation in the nucleic acid sequence of said gene,
e) comparing said first level with said second level.

### Claim 29

A method for determining the mutagenic potential of a petroleum extract, the method comprising:
a) exposing a tester strain of Salmonella typhimurium to said extract,
wherein said tester strain comprises a histidine gene having a preexisting mutation conferring auxotrophy, said mutation located at a predetermined position in the nucleic acid sequence of said gene,
b) growing said tester strain in growth media lacking histidine,
c) detecting the presence of a back-mutation in the nucleic acid sequence at said position, wherein said extract is classified as a mutagen if the level of back-mutation is above a pre-determined background level.

### Claim 30

A method for evaluating a test substance suspected of being a mutagen, the method comprising:
a) exposing a tester strain of Salmonella typhimurium to said substance,
wherein said tester strain comprises a histidine gene having a preexisting mutation conferring auxotrophy, said mutation located at a pre-determined position in said gene,
b) growing said tester strain in growth media lacking histidine, and
c) detecting the presence of a back-mutation at said position, wherein said substance is classified as a mutagen if the level of said back-mutation is above a pre-determined background level.

### Claim 31

A method for determining the mutagenic potential of a test substance, the method comprising:
a) a step for exposing a tester strain of Salmonella typhimurium to said substance,
wherein said tester strain comprises a histidine gene having a preexisting mutation conferring auxotrophy, said mutation located at a pre-determined position in said gene,
b) a step for growing said tester strain in growth media lacking histidine, and
c) a step for detecting the presence of a back-mutation at said position, wherein the presence of said back-mutation correlates with the mutagenic potential of said substance.

### Claim 32

A method for screening a test substance suspected of being a mutagen, the method comprising:
a) a step for providing a tester strain of Salmonella typhimurium,
wherein said tester strain comprises a histidine gene having a preexisting mutation conferring auxotrophy, said mutation located at a pre-determined position in said gene,
b) a step for determining a first level of back-mutation in the nucleic acid sequence of said gene in tester strain which have not been exposed to said substance,
c) a step for exposing tester strain to said substance and determining a second level of back-mutation in the nucleic acid sequence of said gene,
d) a step for comparing said first level with said second level.

### Claim 33

A kit for evaluating the mutagenicity of a test compound, said kit comprising, in separate containers:
a tester strain of Salmonella typhimurium, wherein said tester strain is selected from the group consisting of TA98, TA100, TA102, TA104, TA1535, TA1537, TA1538, and TA97, and
pre-selected PCR primers specific for amplification of a region of the Salmonella histidine operon in said strain, wherein said region contains a preexisting mutation that confers auxotrophy in said strain, wherein said primers generate an amplicon having a length of about 150 base pairs to about 500 base pairs.

### Claim 34 (depends on 33)

The kit of claim 33 further including a reference DNA fragment corresponding to said region for use in a hybridization protocol with said amplicon.

### Claim 35 (depends on 33)

The kit of claim 33 further including S9 fraction in a separate container.

### Claim 36 (depends on 33)

The kit of claim 33 further including a positive control compound.

### Claim 37 (depends on 36)

The kit of claim 36 wherein said control compound includes HC235.

### Claim 38 (depends on 33)

The kit of claim 33 further including a proofreading DNA polymerase.

### Claim 39 (depends on 38)

The kit of claim 38 wherein said polymerase comprises Pho polymerase.

### Claim 40 (depends on 38)

The kit of claim 38 wherein said polymerase comprises Taq polymerase.

### Claim 41

A kit for evaluating the mutagenicity of a test compound, said kit comprising:
pre-selected PCR primers specific for amplification of a region of the Salmonella histidine operon in said strain, wherein said region contains a preexisting mutation that confers auxotrophy in said strain, wherein said primers generate an amplicon having a length of about 150 base pairs to about 500 base pairs.

### Claim 42 (depends on 41)

The kit of claim 41 further including a reference DNA fragment corresponding to said region for use in a hybridization protocol in DHPLC.

### Claim 43

A method for determining the mutagenic potential of a test substance, the method comprising:
a) exposing a bacterial tester strain to said substance in a first media,
wherein said tester strain comprises a gene having a preexisting mutation conferring auxotrophy, said mutation located at a pre-determined position in said gene,
b) growing said tester strain in selective enrichment media to enrich for back-mutation revertants, and
c) detecting the presence of a back-mutation, at the nucleic acid level at said position or nearby, wherein the presence of said back-mutation is distinguished from spontaneous revertant mutations and correlates with the mutagenic potential of said substance.

### Claim 44 (depends on 43)

The method of claim 43 wherein said tester strain comprises Salmonella and said gene comprises the histidine biosynthetic gene.

### Claim 45 (depends on 43)

The method of claim 43 wherein said tester bacteria comprises E. coli and said gene comprises the tryptophan biosynthetic gene.

### Claim 46 (depends on 43)

The method of claim 43 wherein step (a) and step (b) are combined into a single step.

### Claim 47 (depends on 43)

The method of claim 43 wherein said first media and said selective enrichment media are devoid of histidine.

### Claim 48 (depends on 43)

The method of claim 43 wherein said first media and said selective enrichment media contain a limiting amount of histidine.

### Claim 49 (depends on 43)

The method of claim 43 wherein said first media and said selective enrichment media contain a limiting amount of Luria Broth.

### Claim 50 (depends on 43)

The method of claim 43 wherein said first media and said selective enrichment media contain a limiting amount of tester strain growth media to support limited growth of said tester strain while allowing selective enrichment of said back-mutation revertants.

### Claim 51 (depends on 43)

The method of claim 43 wherein enrichment of said back-mutation revertants occurs to a level sufficient for detection of said back mutation at the nucleic acid level.

### Claim 52 (depends on 51)

The method of claim 51 wherein said detection includes a method selected from the group consisting of direct sequencing, minisequencing, pyrosequencing, single-stranded conformation polymorphism, denaturing gradient gel electrophoresis, chemical cleavage, cleavage by mismatch recognition endonuclease, allele specific oligonucleotides, ligase mediated detection of mutations, invader assay, sizing, and denaturing high performance liquid chromatography.

### Claim 53 (depends on 43)

The method of claim 43 wherein a plurality of tester strains are used in step (a).

### Claim 54 (depends on 43)

The method of claim 43 wherein said method is repeated at different doses of said test substance.

### Claim 55 (depends on 43)

The method of claim 43 wherein said tester strain is used in limited amounts to control the level of said background revertants.

### Claim 56 (depends on 43)

The method of claim 43 wherein said tester strain is exposed multiple independent times to said test substance to account for said background revertants.

### Claim 57 (depends on 56)

The method of claim 56 wherein said multiple independent times represent a statistically significant number of repeats to establish a 2-fold increase over said background revertants.

### Claim 58 (depends on 43)

The method of claim 43 wherein said tester strain comprises a plurality of tester strains, in any combination, selected from two or more of the group consisting of TA98, TA100, TA102, TA1535, TA1537, TA1538, and TA97.

### Claim 59 (depends on 58)

The method of claim 58 wherein said tester strain comprises a limited amount of said plurality of tester strains to control the level of said background revertants.

### Claim 60 (depends on 43)

The method of claim 43 wherein said back-mutation comprises an insertion or deletion.

### Claim 61 (depends on 43)

The method of claim 43 wherein said test substance is dissolved in liquid solvent selected the group consisting of DMSO, glycerol formal, dimethyl formamide, formamide, acetonitrile, 95% ethanol, acetone, ethyl glycol, dimethyl ether, 1-methyl-2-pyrrolidone, tetrahydrofurfuryl alcohol, water, and tetrahydrofuran.

### Claim 62 (depends on 61)

The method of claim 61 wherein said liquid solvent is used at a concentration that is not lethal to tester strain.

### Claim 63

A kit for evaluating the mutagenicity of a test compound, said kit comprising in a separate container:
a plurality of tester strains of Salmonella typhimurium, wherein said tester strains are selected from two or more of the group consisting of TA98, TA100, TA102, TA104, TA1535, TA1537, TA1538, and TA97.

### Claim 64 (depends on 63)

The kit of claim 63 where the said tester strains are provided in a ready-to-use format.
